Key statistics
As of last trade, MediciNova Inc (MNOV:NMQ) traded at 1.57, 38.50% above the 52 week low of 1.13 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.60 |
|---|---|
| High | 1.62 |
| Low | 1.57 |
| Bid | 1.56 |
| Offer | 1.58 |
| Previous close | 1.59 |
| Average volume | 51.61k |
|---|---|
| Shares outstanding | 49.15m |
| Free float | 47.73m |
| P/E (TTM) | -- |
| Market cap | 78.14m USD |
| EPS (TTM) | -0.2449 USD |
Data delayed at least 15 minutes, as of Feb 12 2026 17:13 GMT.
More ▼
- MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
- 2026 New Year’s Greetings from the CEO
- MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
- MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
- Message from the CEO to MediciNova Shareholders
- MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
- MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
- MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
- MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
- MediciNova to Present at the LD Micro Main Event XIX Investor Conference
More ▼
